Susan Margaret Sundström
Corporate Officer/Principal chez The University of Southampton
Profil
Susan Margaret Sundström is currently a Principal at The University of Southampton.
Previously, she was a Non-Executive Director at Synairgen Plc from 2003 to 2009, and a Non-Executive Director at Karus Therapeutics Ltd.
She also held a position as a Principal at AstraZeneca PLC.
Postes actifs de Susan Margaret Sundström
| Sociétés | Poste | Début |
|---|---|---|
| The University of Southampton | Corporate Officer/Principal | - |
Anciens postes connus de Susan Margaret Sundström
| Sociétés | Poste | Fin |
|---|---|---|
| SYNAIRGEN PLC | Directeur/Membre du Conseil | 03/09/2009 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SYNAIRGEN PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
